International
The Morning Science

What science found today

‹
 

Research

A CD7-targeted AAV variant enables efficient T and NK cell engineering in vivo

Nature · By Lingjuan Hong ·

The Brief

  • A Nature Biotechnology article reports an AAV variant targeted to CD7 for engineering T and NK cells in vivo.
  • The source summary states that the vector enables efficient T and NK cell engineering in vivo.

Why it matters

It describes a way to deliver genetic engineering to T and NK cells inside the body by targeting a viral vector to CD7, which may inform the development of future cell-based therapies.

Who’s affected

  • researchers in gene therapy and vector design
  • immunology and cell therapy researchers

Nature Biotechnology, Published online: 16 November 2026; doi:10.1038/s41587-026-03344-5 Adeno-associated virus vectors targeted to CD7 enable T and NK cell engineering in vivo.

Timeline

  1. Published online in Nature Biotechnology

  2. nature.com

    A CD7-targeted AAV variant enables efficient T and NK cell engineering in vivo

How do you feel about this?

0 Comments

    A CD7-targeted AAV variant enables efficient T and NK cell engineering in vivo – The Morning Science